A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.

Cancer Med · 2018 · PMC6246941 · PMID 30318751

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant

However, these changes in symptom scores did not reach statistical significance ( P > 0.05), and mean scores stabilized or decreased slightly to levels below baseline across all variables over 24 months of therapy.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.